7:41 PM
 | 
Dec 03, 2012
 |  BC Extra  |  Company News

Germany again rebuffs Trajenta

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) reassessed Trajenta linagliptin from Boehringer Ingelheim GmbH (Ingelheim, Germany) and said the diabetes drug provides "no additional benefit" over sulfonylurea, a comparator requested by Germany's Federal Joint Committee (G-BA). Boehringer said it sees a "clear additional benefit"...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >